The FDA recently approved new doses of durvalumab (Imfinzi®, AstraZeneca) for the treatment of patients with previously treated advanced urothelial carcinoma and unresectable stage III non-small cell lung cancer. "Durvalumab, a selective, high-affinity, engineered human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80, is approved in the US, Japan, and several other countries for the treatment of patients with unresectable, stage III NSCLC whose disease has not progressed following conc...

In patients who have been diagnosed with T1 N0 M0 triple-negative breast cancer (TNBC), age plays a role in whether chemotherapy or radiotherapy will lead to better outcomes for overall survival and breast cancer–specific survival (BCSS), according to the results of a cohort study now published in JAMA Network Open. The investigators, led by Zhen Zhai, MD, of the Department of Breast Surgery in the First Affiliated Hospital in the College of Medicine at Zhejiang University in Hangzhou, China, en...

Using circulating tumor cell (CTC) count to determine whether chemotherapy or endocrine therapy is used improves survival outcomes compared with clinically determined treatment in patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, according to the results of the open-label, randomized phase 3 STIC CTC trial published today in JAMA Oncology. The investigators, led by François-Clément Bidard, MD, PhD, Professor of Medicine at the University of Paris-Sac...

The results of a new study found that patients receiving chemotherapy and radiation therapy simultaneously for abdominopelvic cancers were at higher risk of developing secondary sarcoma compared with patients who received surgery or radiation therapy alone for their treatment. "To our knowledge, this is the largest and most comprehensive series to estimate the risk of secondary sarcoma in a large group of adult patients treated for multiple primary abdominopelvic cancers...

In advanced gastric cancer and gastroesophageal junction cancer, treatment options remain limited. Results of the phase 3 CheckMate 649 and phase 2/3 ATTRACTION-4 studies, both of which investigated chemotherapy with or without nivolumab in patients with previously untreated unresectable, advanced, or recurrent gastric/gastroesophageal junction (G/GEJ) cancer, were recently presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2020. CheckMate 649 reported significant impr...